Cambridge Investment Research Advisors, Inc. Bei Gene, Ltd. Transaction History
Cambridge Investment Research Advisors, Inc.
- $32.9 Billion
- Q2 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 2,815 shares of BGNE stock, worth $638,188. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,815Holding current value
$638,188% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding BGNE
# of Institutions
284Shares Held
32.2MCall Options Held
113KPut Options Held
106K-
Baker Bros. Advisors LP New York, NY8.8MShares$1.99 Billion20.22% of portfolio
-
Primecap Management CO Pasadena, CA5.09MShares$1.15 Billion0.94% of portfolio
-
Capital International Investors Los Angeles, CA4.89MShares$1.11 Billion0.2% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E91.03MShares$234 Million9.68% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.02MShares$231 Million0.03% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...